SAN DIEGO, April 4 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced the exercise by its underwriters of an over-allotment option to purchase 1,500,000 shares of common stock associated with its follow-on stock offering that priced on March 29, 2006. Including the over-allotment shares, the offering will total 11,500,000 shares at $46.50 per share, resulting in expected net proceeds to the company of approximately $508 million.
Morgan Stanley & Co. Incorporated is acting as the sole bookrunning and co-lead manager for the offering. Goldman, Sachs & Co. is acting as a co-lead manager of the offering. Co-managers for the offering are Bear, Stearns & Co. Inc. and Lehman Brothers Inc.
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.
Copies of the prospectus supplement may be obtained from the Prospectus Department of Morgan Stanley & Co. Incorporated (1585 Broadway, New York, New York 10036, phone 212-761-6775, fax 212-761-0211).
Amylin Pharmaceuticals, Inc.
CONTACT: Mark G. Foletta, Senior Vice President, Finance and ChiefFinancial Officer of Amylin Pharmaceuticals, Inc., +1-858-552-2200
Web site: http://www.amylin.com//
